Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study

INTRODUCTION: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine implicated in airway inflammation in asthma, from binding to its heterodimeric receptor. In the PATHWAY phase 2b study, tezepelumab significantly reduced exacerbation rate...

Descripción completa

Detalles Bibliográficos
Autores principales: Corren, Jonathan, Karpefors, Martin, Hellqvist, Åsa, Parnes, Jane R, Colice, Gene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810672/
https://www.ncbi.nlm.nih.gov/pubmed/33469316
http://dx.doi.org/10.2147/JAA.S286036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810672/
https://www.ncbi.nlm.nih.gov/pubmed/33469316
http://dx.doi.org/10.2147/JAA.S286036

Ejemplares similares